nach oben

Erschienen in:

27.05.2020 | COVID-19 | Editorial Zur Zeit gratis

Navigating COVID-19 in the developing world

verfasst von: Bridget Hodkinson, Prasun Singh, Ayanda Gcelu, Wilson Bautista-Molano, Guillermo Pons-Estel, Deshiré Alpízar-Rodríguez

Erschienen in: Clinical Rheumatology | Ausgabe 7/2020

Einloggen, um Zugang zu erhalten

Excerpt

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been declared a pandemic and a global public health emergency by the World Health Organization. This condition began in China in December 2019, was exported by international travellers and is now spreading by community transmission with cases reported in every country around the world. Over 3 million people are infected as of 2 May 2020, with over 240,000 reported deaths [1]. The case fatality rate is estimated at 1–5%, and no effective treatment has been clearly demonstrated for patients severely affected by the disease caused by SARS-CoV-2, named COVID-19. …

World Health Organisation. Coronavirus disease Pandemic. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed

D’Antiga L (2020) Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl Mar 20. https://doi.org/10.1002/lt.25756

Venerito V, Lopalco G, Iannone F (2020) COVID-19, rheumatic diseases and immunosuppressive drugs: an appeal for medication adherence. Rheumatol Int 40(5):827–828

Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R (2020) COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev 19(5):102523

Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P et al (2020) In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. https://doi.org/10.1093/cid/ciaa237

Yazdany J, Kim AHJ (2020) Use of hydroxychloroquine and chloroquine during the COVID-19 pandemic: what every clinician should know. Ann Intern Med Mar 31. https://doi.org/10.7326/M20-1334

Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, Ambati J. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. medRxiv 2020.04.16.20065920. https://doi.org/10.1101/2020.04.16.20065920

Lu CC, Chen MY, Chang YL (2020) Potential therapeutic agents against COVID-19: what we know so far. J Chin Med Assoc. https://doi.org/10.1097/JCMA.0000000000000318

Gates B (2020) Responding to Covid-19—a once-in-a-century pandemic? N Engl J Med 382(18):1677–1679

10.

Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D (2009) The burden of noncommunicable diseases in South Africa. Lancet. 374(9693):934–947CrossRef

11.

Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA et al (2014) Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9947):1005–1070CrossRef

12.

Cohen C, Moyes J, Tempia S, Groom M, Walaza S, Pretorius M et al (2013) Severe influenza-associated respiratory infection in high HIV prevalence setting, South Africa, 2009–2011. Emerg Infect Dis 19(11):1766–1774CrossRef

13.

Lin JC, Nichol KL (2001) Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 161(3):441–446CrossRef

14.

von Mollendorf C, Hellferscee O, Valley-Omar Z, Treurnicht FK, Walaza S, Martinson NA et al (2018) Influenza viral shedding in a prospective cohort of HIV-infected and uninfected children and adults in 2 provinces of South Africa, 2012–2014. J Infect Dis 218(8):1228–1237CrossRef

15.

Walaza S, Cohen C, Nanoo A, Cohen AL, McAnerney J, von Mollendorf C et al (2015) Excess mortality associated with influenza among tuberculosis deaths in South Africa, 1999–2009. PLoS One 10(6):e0129173CrossRef

16.

Joob B, Wiwanitkit V (2020) SARS-CoV-2 and HIV. J Med Virol. https://doi.org/10.1002/jmv.25782

17.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G et al (2020) A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 382(19):1787–1799

18.

Saavedra-Velasco M, Chiara-Chilet C, Pichardo-Rodriguez R, Grandez-Urbina A, Inga Berrospi F (2020) Coinfección entre dengue y COVID-19: Necesidad de abordaje en zonas endémicas. Revista De La Facultad De Ciencias Médicas De Córdoba 77:52–54CrossRef

19.

Mody GM (2017) Rheumatology in Africa-challenges and opportunities. Arthritis Res Ther 19(1):49CrossRef

20.

Rhodes A, Ferdinande P, Flaatten H, Guidet B, Metnitz PG, Moreno RP (2012) The variability of critical care bed numbers in Europe. Intensive Care Med 38(10):1647–1653CrossRef

21.

World Health Organisation. Global Health Observatory Data https://www.who.int/gho/publications/world_health_statistics/en/. Accessed 6 April 2020

22.

Wang J, Xu C, Wong YK, He Y, Adegnika AA, Kremsner PG et al (2020) Preparedness is essential for malaria-endemic regions during the COVID-19 pandemic. Lancet 395(10230):1094–1096

23.

Zurcher K, Zwahlen M, Ballif M, Rieder HL, Egger M, Fenner L (2016) Influenza pandemics and tuberculosis mortality in 1889 and 1918: analysis of historical data from Switzerland. PLoS One. 11(10):e0162575CrossRef

24.

Cardona-Ospina JA, Villamil-Gomez WE, Jimenez-Canizales CE, Castaneda-Hernandez DM, Rodriguez-Morales AJ (2015) Estimating the burden of disease and the economic cost attributable to chikungunya, Colombia, 2014. Trans R Soc Trop Med Hyg. 109(12):793–802CrossRef

25.

World Health Organisation. Report of the WHO-China Joint Mission on Coronavirus Disease 2019. https://publicintelligence.net/who-china-mission-covid-19/. Accessed 6 April 2020

26.

United Nations. World Population Prospects 2019 https://population.un.org/wpp/Maps/. Accessed 6 April 2020

27.

Li W, Moore MJ, Vasilieva N, Sui J, Wong SK, Berne MA et al (2003) Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 426(6965):450–454CrossRef

28.

Yang JM, Meng X, Xue F, Zhang Y, Zhang C (2020) ACE2 in the context of 2019-nCoV infection: friend or foe? Zhonghua Xin Xue Guan Bing Za Zhi 48(0):E012

29.

Mengesha HG, Petrucka P, Spence C, Tafesse TB (2019) Effects of angiotensin converting enzyme gene polymorphism on hypertension in Africa: a meta-analysis and systematic review. PLoS One. 14(2):e0211054CrossRef

30.

Pinheiro DS, Santos RS, Jardim P, Silva EG, Reis AAS, Pedrino GR et al (2019) The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients. PLoS One 14(8):e0221248CrossRef

31.

Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X et al (2020) Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 6:11CrossRef

32.

Rodriguez-Morales AJ, Gallego V, Escalera-Antezana JP, Mendez CA, Zambrano LI, Franco Paredes C et al (2020) COVID-19 in Latin America: the implications of the first confirmed case in Brazil. Travel Med Infect Dis. https://doi.org/10.1016/j.tmaid.2020.101613

33.

Patil NG, Chan Y, Yan H (2003) SARS and its effect on medical education in Hong Kong. Med Educ 37(12):1127–1128CrossRef

34.

Kononowicz AA, Woodham LA, Edelbring S, Stathakarou N, Davies D, Saxena N et al (2019) Virtual patient simulations in health professions education: systematic review and meta-analysis by the digital health education collaboration. J Med Internet Res 21(7):e14676CrossRef

35.

Motsepe family & associates join Rupert and Oppenheimer families in donating R1bn to deal with COVID-19 pandemic. CNBC Africa. 2020. https://www.forbesafrica.com/billionaires/2020/03/30/motsepe-family-associates-join-rupert-andoppenheimer-families-in-donating-r1-billion-to-deal-with-covid-19-pandemic/. Accessed 6 April 2020

Titel: Navigating COVID-19 in the developing world
verfasst von: Bridget Hodkinson
Prasun Singh
Ayanda Gcelu
Wilson Bautista-Molano
Guillermo Pons-Estel
Deshiré Alpízar-Rodríguez
Publikationsdatum: 27.05.2020
Verlag: Springer International Publishing
Schlagwort: COVID-19
Erschienen in: Clinical Rheumatology / Ausgabe 7/2020
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05159-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Navigating COVID-19 in the developing world

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2020

Correction to: Associations between serumIL-8 and knee symptoms, joint structures, and cartilage or bone biomarkers in patients with knee osteoarthritis

Clinical phenotypes based on clinical prognostic factors in patients with secondary hip osteoarthritis: preliminary findings from a prospective cohort study

Management of antiphospholipid syndrome

Correction to: Serum substance P: an indicator of disease activity and subclinical inflammation in rheumatoid arthritis

COVID-19 with rheumatic diseases: a report of 5 cases

Serum adipokine levels in patients with sarcoidosis

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin